T: +1 215 994 2205
F: +1 215 655 2205

Related Events

Related Publications

Related News

Steven E. Bizar, Co-leader of the antitrust/competition practice, is a first chair trial lawyer well regarded for his success in the defense of antitrust class action and Section 1 Sherman act cases and his trial of complex commercial disputes in court and before arbitrators. His more than two decades of experience span a diverse range of antitrust and trade regulation, contracts and business torts, government investigations, insurance and reinsurance, securities and corporate governance matters. Mr. Bizar regularly represents multinational and domestic companies, partnerships, and individuals, including officers and directors, on issues arising across a broad spectrum of industries, including chemicals, financial services, construction materials, healthcare, pharmaceuticals, wholesale distribution, gaming, technology, and telecommunications.

Mr. Bizar advises clients around the globe on complex business disputes and litigates high-profile trial and appellate matters in federal and state courts and before arbitral tribunals. He has appeared in courts across the United States handling a wide variety of litigation matters, including the trial defense of multidistrict class actions, “bet-the-company” lawsuits, and contract and tort disputes arising from clients' commercial activities. Mr. Bizar also has significant appellate experience and has secured wins in the areas of class certification, antitrust, securities fraud pleading standards, full faith and credit/res judicata and forum non conveniens. Mr. Bizar has handled international arbitrations through to award under the procedural rules of leading arbitral institutions, including the AAA-ICDR and ICC. He also represents clients in connection with government antitrust and securities fraud investigations and in enforcement and other proceedings before agencies and self-regulatory organizations.

Noted as “one of the go-to lawyers for antitrust defense” Mr. Bizar is repeatedly ranked for antitrust (Band 1) and commercial litigation (Band 2) by Chambers USA. Mr. Bizar is a Fellow of the International Academy of Trial Lawyers and the American Bar Foundation, both invitation-only honorary organizations that select legal professionals who have demonstrated outstanding skill and ability as well as a dedication to advancing justice within their own communities and promoting the rule of law internationally. He is listed in The Best Lawyers in America, Best Lawyers in Philadelphia and Global Competition Review's Who's Who for antitrust law and is regularly nominated for the Pennsylvania Super Lawyers and the Corporate Counsel Super Lawyers lists. In 2015, the National Law Journal recognized Mr. Bizar as a “Mergers & Acquisitions and Antitrust Trailblazer” and he was also included in the exclusive BTI Consulting 2015 and 2009 “Client Service All-Star” lists, which named a select group of litigators nationwide based solely on direct client feedback.

Mr. Bizar is a frequent author and commentator regarding antitrust litigation in the chemicals, healthcare, pharmaceuticals and vitamin industries. He has been featured in Bloomberg, Global Competition Review, Law360, Los Angeles Times, The Associated Press, Reuters, The Chicago Tribune, The Legal Intelligencer, The National Law Journal, and other prominent legal publications as well as on the regional television program Law Journal TV.

In the community, Mr. Bizar currently serves as President of the Philadelphia Bar Foundation, the charitable arm of the Philadelphia legal community whose mission is to ensure that the underprivileged have equal access to justice and publicly available services. A former chair of the Philadelphia Bar Association’s Federal Courts and State Civil Rules Committees, Mr. Bizar also serves as an investigative team member for the Commission on the Selection and Retention of Judges, which evaluates candidates for the state bench.

Prior to joining Dechert, Mr. Bizar served as an executive shareholder and litigation shareholder at another national law firm, where he focused on business disputes and class action defense, including at trial, of antitrust, securities fraud, and complex commercial cases.

Significant Representations


Antitrust
  • Defending a leading gypsum wallboard manufacturer as lead and liaison counsel in the defense of antitrust suits filed by direct, indirect and opt-out purchasers.
  • Resolved a claim against a Swedish telecommunications firm for no money or admission of liability in an antitrust case challenging its conduct in a standards setting organization.
  • Argued the successful Rule 23(f) appeal resulting in the decertification of a class of hydrogen peroxide purchasers and the clarification of class certification standards in a landmark ruling from the U.S. Court of Appeals for the Third Circuit in a Sherman Act §1 case.
  • Defeated class certification after a three-day evidentiary hearing in a federal antitrust class action claiming price-fixing for plastics additives under Sherman Act § 1.
  • Defended a prominent discount retailer against state law unfair competition claims.
  • Defended a pharmacy benefits manager against putative class action claims asserted under §1 of the Sherman Act based on alleged conspiracies with other pharmacy benefits managers and with their respective clients to depress the prices paid to independent retail pharmacies for filling prescriptions.
  • Defeated an antitrust claim brought under Sherman Act § 1 against a hospital system alleging involvement in conspiracy to depress salaries of registered nurses in the Albany, New York area.
  • Defended a multi-state Catholic hospital system, on putative class action claims alleging price gouging in its affiliated hospital’s pricing of health care services to the uninsured.
  • Defeated a claim by a putative class of foreign purchasers of the chemical product MCAA brought under Sherman Act §1.
  • Defended a French multinational chemical manufacturing company against direct and indirect purchaser and opt-out class action antitrust lawsuits filed in federal and state courts across the country challenging its activities with regard to four categories of products.
  • Represented a pharmaceutical wholesaler in a US$11 billion antitrust class action lawsuit and 100 opt-out lawsuits, including three summary judgment motions, an 11-week jury trial in federal court in Chicago, and three separate appeals to the Seventh Circuit Court of Appeals.
  • Defended an antitrust “group boycott” lawsuit against a pharmaceutical distributor, resulting in a dismissal on a Rule 12 motion.
  • Counseled various clients on distribution issues under the Sherman and Robinson-Patman Acts.
  • Developed and implemented antitrust compliance and training programs for clients in various industries, including chemicals and wholesale distribution.

Complex Commercial
  • Defended the Secretary of State for the Commonwealth of Pennsylvania through two successful summary judgment motions and a Pennsylvania Supreme Court argument and victory against a lawsuit challenging the process used to certify direct recording electronic voting systems for use in Pennsylvania.
  • Represented a French respondent in defeating a US$28 million claim in an AAA-ICDR arbitration in New York brought by a U.S. claimant for cancellation of a geographic product swap agreement. 
  • Represented Cook Composites and Polymers in a five-week federal jury trial stemming from a US$405 million lawsuit, before trebling, filed by Viking Yacht Company and Post Marine, resulting in a complete trial victory upheld on appeal.
  • Represented a foreign manufacturer as plaintiff against the U.S. Customs and Border Protection Service on a case in which the U.S. Court of International Trade found that the client’s inkjet colorant products were being misclassified as dyes instead of inks under the Harmonized Tariff, resulting in lower duties.
  • Defended a logistics services company in a federal securities fraud class action lawsuit which resulted in a dismissal, later affirmed on appeal.
  • Defended directors and officers of a Fortune 25 company in shareholder derivative lawsuits.
  • Defended a corporate client in a shareholder derivative case of first impression, which established that §304 of the Sarbanes-Oxley Act does not provide a private right of action for disgorgement against a corporate client's CEO and CFO.
  • Represented the Board of Directors of a major corporation in derivative lawsuits and a Delaware Section 220 books and records proceedings based on the equity compensation awarded to the company’s CEO.
  • Vindicated a foreign reinsurer's contractual rights in multi-state insurance company insolvency proceedings and in reinsurance contract litigation.
  • Tried an adversary proceeding in federal bankruptcy court challenging a client's decision not to close a multimillion-dollar asset purchase transaction.
  • Defended a hospital system against class and collective action lawsuits under the FLSA and analogous state statutes.
  • Obtained a mandatory TRO in Delaware Chancery Court requiring one of the world's largest chemical manufacturers to supply his client a key chemical monomer despite its force majeure declaration.
  • Defended French and American chemical manufacturers in disputes in Texas state court and in arbitration with one of the world’s largest chemical manufacturers over supply, swap, plant investment, and plant services agreements.
  • Represented a leading chemical manufacturing firm as claimant and counter-respondent in an ICC arbitration with a Korean firm and its U.S. affiliate arising from alleged breaches of joint development and sale and purchase agreements.
  • Defended a multinational specialty chemical manufacturing company in a multimillion-dollar dispute with two former distributors of its EPA-regulated product.
  • Defended a chemical manufacturing firm against breach of contract and business tort claims based on a customer’s dissatisfaction with its resin product.
  • Defended a leading industrial gas manufacturer against a breach of contract claim in state court arising from an allocation following a force majeure declaration.
  • Prosecuted claims in Pennsylvania state court for a temporary restraining order and preliminary injunction barring the misappropriation of trade secrets on behalf of a pharmaceutical manufacturer.
  • Defended a biotech manufacturing company in an AAA arbitration against alleged breach of warranty and fraud claims stemming from its manufacture of active pharmaceutical ingredients.
  • Defended a pharmaceutical wholesaler against a breach of contract/fraud lawsuit in federal court in New Jersey.

Reported Cases
  • Banfield, et al. v. Cortes, Secretary of the Commonwealth, 110 A.3d 155 (Pa. 2015) and 51 A.3d 300 (Comm. Ct. 2012).
  • Missouri River Historical Development, Inc. v. Penn National Gaming, Inc., 283 F.R.D. 501 (N.D. IA 2012).
  • Richelson v. Yost, et. al., No. 10-1342, 2010 WL 3563108 (E.D. Pa. Sept. 9, 2010).
  • In re Plastics Additives Antitrust Litigation, No. 03-CV-2038, 2010 WL 3431837 (E.D. Pa. Aug. 31, 2010).
  • Arkema Inc. v. The Dow Chemical Co., et al., Civ. No. 5479-VCP (Del. Ct. Chancery May 14, 2010).
  • Viking Yacht Company, et al., v. Composites One LLC, et al., No. 05-cv-538 (D.N.J.) and Nos. 09-3417 and 09-3558 (3rd Cir. July 1, 2010).
  • In re Hydrogen Peroxide Antitrust Litigation, No. 07-1689, 552 F.3d 305 (3rd Cir. Dec. 30, 2008).
  • Avecia, Inc. v. United States, 469 F. Supp. 2d 1269 (Ct. Int’l Trade 2006).
  • Colomar v. Mercy Hospital, Inc. and Catholic Health East, Inc., Case No. 05-22409-Civ. (S.D. Fla Nov. 8, 2006) (Seitz).
  • Globis Capital Partners, L.P. v. Stonepath Group, Inc., No.06-2560, 2007 WL 1977236, (3d Cir. July 10, 2007).
  • Stonepath Group Sec. Litigation, No. 04-CV-4515, 2006 WL 980767 (E.D. Pa. Apr. 3, 2006).
  • Stonepath Group Sec. Litigation, 397 F.Supp.-2d 575, 2005 WL 2810791 (E.D. Pa. 2005).
  • Neer v. Pelino, et al., 389 F.Supp.2d 648 (E.D. Pa. Sept. 27, 2005).
  • Latino Quimica-Amtex S.A. v. Akzo Nobel Chemicals B.V., et al., 2005 WL 2207017, 2005-2 Trade Cases (CCH) P. 74,974 (S.D.N.Y. 2005).
  • Amalgamated Bank v. Yost, et al., 2005 WL 226117 (E.D. Pa. Jan. 31, 2005).
  • GE Frankona Reinsurance Company, Ltd., et al. v. Legion Indemnity Company in Liquidation, 373 Ill. App. 969, 870 N.E. 2d 829 (Ill. App. 1st Dist. 2007).
  • M. Diane Koken, Insurance Commissioner, Commonwealth of Pennsylvania v. Legion Insurance Company, 865 A.2d 945, Pa.Cmwlth., December 09, 2004 (No. 183 M.D. 2002).
  • Bennett, et al. v. Cardinal Health Marmac Distributors, Inc., et al., 2003 WL 21738604 (E.D.N.Y. 2003).
  • Walnut Equipment Leasing Co., Inc., No. 97-19699DWS, 00-864, 2003 WL 22213746 (Bankr. E.D. Pa. Sept. 12, 2003).
  • Walnut Equipment Leasing Co., Inc., No. 97-19699DWS, 00-864, 2003 WL 21262710 (Bankr. E.D. Pa. May 28, 2003).
  • Walnut Equipment Leasing Co., Inc., 2002 WL 31994477 (Bankr. E.D. Pa., Dec 13, 2002) (No. 97-19699DWS, 00-0864).
  • Bracco Diagnostics, Inc. v. Bergen Brunswig Drug Co., 226 F. Supp. 2d 557 (D.N.J. 2002).
  • Brand Name Prescription Drugs Antitrust Litigation, 288 F.3d 1028 (7th Cir. 2002).
  • General Instrument Securities Litigation, 209 F.Supp.2d 423, Fed. Sec. L. Rep. P 91,667 (E.D. Pa. 2001).
  • Morse v. Dun & Bradstreet, Inc., 87 F.Supp.2d 901 (D. Minn. 2000).
  • Brand Name Prescription Drugs Antitrust Litigation, 186 F.3d 781 (7th Cir. 1999).
  • Brand Name Prescription Drugs Antitrust Litigation, 1999 W.L. 33889, 1999-1 Trade Cases P. 72, 446 (N.D. Ill. Jan. 19, 1999).
  • Abbott Laboratories v. Durrett, 746 So. 2d 316, 1999-1 Trade Cases P 72,559 (Ala. 1999).
  • Brand Name Prescription Drugs Antitrust Litigation, 177 F.R.D. 414 (N.D. Ill. 1997) (No. 94 C 897).
  • Sternberg v. Satco Casting Service, Inc., CIV. A. 95-7084, 1997 WL 230794, 42 U.S.P.Q.2d 1889 (E.D. Pa., Apr 30, 1997).
  • Sternberg v. Satco Casting Service, Inc., CIV. A. 95-7084, 1996 WL 745287 (E.D. Pa., Dec 20, 1996).
  • Brand Name Prescription Drugs Antitrust Litigation, 878 F. Supp. 1078, 1995-1 Trade Cases P 71,020 (N.D. Ill. 1995).
  • Brand Name Prescription Drugs Antitrust Litigation, 867 F. Supp. 1338, 1995-1 Trade Cases P 70,924 (N.D. Ill. 1994).
  • Liberty Sales Associates, Inc. v. Dow Corning Corp., 816 F. Supp. 1004 (D.N.J. 1993).
  • Blake v. Bank of New York, No. 90 CIV. 4202 (JFK),1992 WL 183632 (S.D.N.Y., Jul 23, 1992).
  • Lony v. E.I. Du Pont de Nemours & Co., 935 F.2d 604 (3rd Cir. 1991).

Includes matters handled at Dechert or prior to joining the firm.

Education

Brandeis University, B.S., 1984, summa cum laude, Phi Beta Kappa
Brandeis University, M.A., 1987
Columbia Law School, J.D., 1988, Harlan Fiske Stone Scholar

Court Admissions

United States District Court for the Eastern District of Pennsylvania
United States District Court for the Western District of Pennsylvania
United States District Court for the Middle District of Pennsylvania
United States District Court for the Southern District of New York
United States District Court for the Eastern District of New York
United States District Court for the Northern District of New York
United States Court of International Trade
United States Court of Appeals for the Second Circuit
United States Court of Appeals for the Third Circuit
United States Court of Appeals for the Seventh Circuit

Bar Admissions/Qualifications

Pennsylvania
New York

Memberships

Fellow, International Academy of Trial Lawyers
Fellow, American Bar Foundation
Fellow, Litigation Counsel of America
The Lawyers Club of Philadelphia
Litigation and Antitrust Sections, American Bar Association
President and Board of Trustees Member, Philadelphia Bar Foundation
Board of Visitors, Columbia Law School
Harlan Fiske Stone Council, Columbia Law School
Dean’s Development Council, Columbia Law School
Alumni Association, Columbia Law School